ABPI appoints communications director
pharmafile | November 11, 2010 | Appointment | Research and Development, Sales and Marketing | ABPI, Amanda Callaghan, Royal College of Nursing, appointment, research and development, sales and marketing
UK industry body the ABPI has appointed Amanda Callaghan director of corporate communications.
She starts the role on 31 January 2011, when she will be responsible for supporting the APBI Board, director general and senior leadership team in all aspects of communications.
Amanda said: “This is an exciting but challenging time and I am looking forward to working with ABPI members and staff to ensure that the pharmaceutical industry plays a leading and supportive role in the development of the new health agenda.”
She is currently director of communications at the Royal College of Nursing (RCN), where she leads government, stakeholder and media relations as well as digital and internal communications.
Amanda has also been responsible for developing and leading the communications strategy and campaigning for the RCN, and also had great success in partnership activities with stakeholder organisations, the Department of Health, ministers, the media and the membership.
She first joined the RCN in 2001 as senior parliamentary officer, became head of communications in 2004 and subsequently joined the executive team in 2007 as director of communications.
In her new role she will report directly to the director general and will be a member of the ABPI’s senior leadership team. In turn the ABPI’s communications and government affairs teams will report to Amanda.
Dr Richard Barker, director general of the ABPI, said: “We are fortunate to have such an accomplished healthcare communicator able to take the profile of the industry and the ABPI to new levels.”
Related Content
PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …
AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …
Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months
TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …
